Matches in SemOpenAlex for { <https://semopenalex.org/work/W1904863312> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W1904863312 abstract "Background Boceprevir and telaprevir are two new drugs approved by the European Medicines Agency for the treatment of hepatitis C genotype 1. They are used in combination with ribavirin and peg-interferon to increase the response to treatment. Purpose To analyse the evolution of the viral load and the adverse effects of boceprevir and telaprevir, at week 12 of treatment. Materials and Methods We undertook a prospective observational study from November 2011 to October 2012 of patients who started treatment with boceprevir and telaprevir. Patients were monitored for 12 weeks after initiation of triple therapy. We also analysed the incidence of adverse effects during treatment. The data collected were: age, sex, grade of fibrosis, type of patient, baseline viral load, and viral load at weeks 4, 8 and 12. The data were consulted in the medical records of patients through the IMDHv.50 programme. Results A total of 31 patients were followed up, eight treated with boceprevir and 23 with telaprevir. The median of age was 60 years. Regarding the type of patient, 10 were treatment naive, 5 were relapsers, 7 non-responders, 4 presented side effects in previous treatment and 5 were partial non-responders. The median viral load was 2,682,000 IU/ml. At week 12, undetectable viral load was found in 26 (83.8%) patients (6 in the boceprevir group and 20 in the telaprevir group). Five patients (16.1%) had to discontinue treatment, four (12.9%) had >1000 IU/ml at week 12 and one (3%) due to pancreatitis. Adverse events observed during treatment are shown in the table. Conclusions The data show an early decrease in the viral load of patients treated with triple therapy, becoming undetectable by week 12 in most cases. The side effects differed from those described in clinical trials, so more studies and post-marketing pharmacovigilance are needed. No conflict of interest." @default.
- W1904863312 created "2016-06-24" @default.
- W1904863312 creator A5006334273 @default.
- W1904863312 creator A5027632135 @default.
- W1904863312 creator A5039139606 @default.
- W1904863312 creator A5055315247 @default.
- W1904863312 creator A5065918795 @default.
- W1904863312 creator A5069004813 @default.
- W1904863312 date "2013-03-01" @default.
- W1904863312 modified "2023-09-24" @default.
- W1904863312 title "CPC-045 Efficacy and Safety of Boceprevir and Telaprevir at Week 12 of Treatment: Abstract CPC-045 Table 1" @default.
- W1904863312 doi "https://doi.org/10.1136/ejhpharm-2013-000276.502" @default.
- W1904863312 hasPublicationYear "2013" @default.
- W1904863312 type Work @default.
- W1904863312 sameAs 1904863312 @default.
- W1904863312 citedByCount "0" @default.
- W1904863312 crossrefType "journal-article" @default.
- W1904863312 hasAuthorship W1904863312A5006334273 @default.
- W1904863312 hasAuthorship W1904863312A5027632135 @default.
- W1904863312 hasAuthorship W1904863312A5039139606 @default.
- W1904863312 hasAuthorship W1904863312A5055315247 @default.
- W1904863312 hasAuthorship W1904863312A5065918795 @default.
- W1904863312 hasAuthorship W1904863312A5069004813 @default.
- W1904863312 hasBestOaLocation W19048633121 @default.
- W1904863312 hasConcept C126322002 @default.
- W1904863312 hasConcept C142462285 @default.
- W1904863312 hasConcept C159047783 @default.
- W1904863312 hasConcept C197934379 @default.
- W1904863312 hasConcept C2522874641 @default.
- W1904863312 hasConcept C2776408679 @default.
- W1904863312 hasConcept C2776461080 @default.
- W1904863312 hasConcept C2777159539 @default.
- W1904863312 hasConcept C2778159067 @default.
- W1904863312 hasConcept C2780040827 @default.
- W1904863312 hasConcept C71924100 @default.
- W1904863312 hasConcept C90924648 @default.
- W1904863312 hasConceptScore W1904863312C126322002 @default.
- W1904863312 hasConceptScore W1904863312C142462285 @default.
- W1904863312 hasConceptScore W1904863312C159047783 @default.
- W1904863312 hasConceptScore W1904863312C197934379 @default.
- W1904863312 hasConceptScore W1904863312C2522874641 @default.
- W1904863312 hasConceptScore W1904863312C2776408679 @default.
- W1904863312 hasConceptScore W1904863312C2776461080 @default.
- W1904863312 hasConceptScore W1904863312C2777159539 @default.
- W1904863312 hasConceptScore W1904863312C2778159067 @default.
- W1904863312 hasConceptScore W1904863312C2780040827 @default.
- W1904863312 hasConceptScore W1904863312C71924100 @default.
- W1904863312 hasConceptScore W1904863312C90924648 @default.
- W1904863312 hasLocation W19048633121 @default.
- W1904863312 hasOpenAccess W1904863312 @default.
- W1904863312 hasPrimaryLocation W19048633121 @default.
- W1904863312 hasRelatedWork W1974027259 @default.
- W1904863312 hasRelatedWork W1988398961 @default.
- W1904863312 hasRelatedWork W2010665223 @default.
- W1904863312 hasRelatedWork W2045331461 @default.
- W1904863312 hasRelatedWork W2052259507 @default.
- W1904863312 hasRelatedWork W2053367508 @default.
- W1904863312 hasRelatedWork W2061468153 @default.
- W1904863312 hasRelatedWork W2080484450 @default.
- W1904863312 hasRelatedWork W2120204570 @default.
- W1904863312 hasRelatedWork W2128122488 @default.
- W1904863312 hasRelatedWork W2154449658 @default.
- W1904863312 hasRelatedWork W2173840206 @default.
- W1904863312 hasRelatedWork W2317100255 @default.
- W1904863312 hasRelatedWork W2327673920 @default.
- W1904863312 hasRelatedWork W2335763907 @default.
- W1904863312 hasRelatedWork W2413331531 @default.
- W1904863312 hasRelatedWork W2414504708 @default.
- W1904863312 hasRelatedWork W2618945960 @default.
- W1904863312 hasRelatedWork W2780778361 @default.
- W1904863312 hasRelatedWork W3150495739 @default.
- W1904863312 isParatext "false" @default.
- W1904863312 isRetracted "false" @default.
- W1904863312 magId "1904863312" @default.
- W1904863312 workType "article" @default.